# Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
Canonical URL: https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-w-c8a2a4f7
Ticker: TRDA
Company: Entrada Therapeutics
Source: Entrada Therapeutics
Published: 2026-05-06 20:30 EST
## Summary

Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. ...

## Article Body
Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results.

The webcast can be accessed by visiting the Investor Relations section of the Company’s website at www.entradatx.com . Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here . The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call.

About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com , and follow us on LinkedIn .

Investor Contact Karla MacDonald Chief Corporate Affairs Officer kmacdonald@entradatx.com

Patient Advocacy Contact Sarah Friedhoff Head of Patient Advocacy patientadvocacy@entradatx.com

Media Contact Megan Prock McGrath CTD Comms, LLC megan@ctdcomms.com
## Recent Company News
- 2026-06-02 11:00 EST — [Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study](https://biopharmsignal.com/news/TRDA/independent-safety-data-monitoring-committee-recommends-initiation-of-cohort-2-a-2a48ec2d) — Source: Entrada Therapeutics
- 2026-06-01 20:30 EST — [Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--4f6f3117) — Source: Entrada Therapeutics
- 2026-05-07 11:10 EST — [Entrada Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2026-financial-results-4b45cf5b) — Source: Entrada Therapeutics
- 2026-05-07 11:00 EST — [Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-positive-topline-results-from-cohort-1-of-partici-8bfbed27) — Source: Entrada Therapeutics
- 2026-05-06 20:30 EST — [Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-w-c8a2a4f7) — Source: Entrada Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)